LLY - Is It Too Late to Buy Eli Lilly Stock Now?
2024-03-02 08:15:00 ET
Eli Lilly (NYSE: LLY) is the largest healthcare company in the world by market capitalization. With dividends reinvested, the company's stock is up an eye-popping 1,530% over the past 10 years.
But over the last year, in particular, Lilly's stock has enjoyed an unprecedented run, fueled by interest in the weight-loss market. Following is a deep dive into Lilly's position in diabetes and obesity and a look at whether the company has enough catalysts outside these markets to keep up its momentum.
The weight-loss market is currently being disrupted by a class of medications called glucagon-like peptide-1 (GLP-1). Popular GLP-1 treatments include Ozempic, Wegovy, and Rybelsus -- all of which are produced by Lilly's Danish rival, Novo Nordisk .
For further details see:
Is It Too Late to Buy Eli Lilly Stock Now?